COX-2 inhibitors in cancer treatment and prevention, a recent development

Anti-Cancer Drugs

Volumn 13, Issue 2, 2002, Pages 127-137

  Xu, Xiao Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer prevention; Cyclooxygenase; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CARCINOGEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GROWTH FACTOR; IBUPROFEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; RETINOIC ACID RECEPTOR BETA; RETINOID; TUMOR PROMOTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; ENZYME INHIBITION; ESOPHAGUS CANCER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNITY; INFLAMMATION; LUNG CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTATE CANCER; RADIOTHERAPY; SHORT SURVEY; SKIN CANCER; TUMOR CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036191540     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200202000-00003     Document Type: Short Survey

References (123)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. Aspirin selectively inhibits prostaglandin production in human platelets
3. Reduced risk of large-bowel adenomas among aspirin users
4. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
5. Aspirin use, reduced risk of fatal colon cancer
6. Aspirin use risk of fatal cancer
7. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
8. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
9. Aspirin and reduced risk of esophageal carcinoma
10. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice
11. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398
12. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
13. Non-steroidal anti-inflammatory drugs and bladder cancer prevention
14. Celecoxib inhibits N-bu tyl-N- (4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
15. Pharmacologic management of Alzheimer disease part III: Nonsteroidal antiinflammatory drugs - Emerging protective evidence?
16. Risk of Alzheimer's disease and duration of NSAID use
17. Cyclooxygenase-2 inhibitors in tumorigenesis (part II)
18. Cyclooxygenase-2 inhibitors in tumorigenesis (part I)
19. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells
20. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2
21. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
22. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
23. Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells
24. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
25. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
26. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents
27. Prostaglandins from tumours of human large bowel
28. Human esophageal carcinoma cell lines: Prostaglandin production, biological properties, and behavior in nude mice
29. 2 in oesophageal carcinogenesis
30. Aspirin and the potential role of prostaglandins in colon cancer
31. Host cyclooxygenase-2 modulates carcinoma growth
32. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
33. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas
34. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
35. Cyclooxygenase-2: A novel target for cancer chemotherapy?
36. Anti-inflammatory drugs and their mechanism of action
37. Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway in esophageal cancer cells
38. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway
39. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
40. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib
41. Cyclooxygenase-independent actions of cyclooxygenase inhibitors
42. Cancer research, anti-infiammatories inhibit cancer growth - But how?
43. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells
44. Intracellular unesterified arachidonic acid signals apoptosis
45. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
46. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice
47. The effect of sodium salicylate and aspirin on NF-kappa B
48. Colorectal cancer and nonsteroidal anti-inflammatory drugs
49. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
50. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
51. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
52. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development
53. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
54. Suppression of intestinal polyposis in Apc delta716 knockout mige by inhibition of cyclooxygenase 2 (COX-2)
55. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
56. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
57. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
58. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
59. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398
60. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
61. Antitumoral activity of indomethacin on experimental esophageal tumors
62. Further studies on the therapeutic effect of indomethacin on esophageal tumors
63. Cyclooxygenase-2 expression in human esophageal carcinoma
64. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
65. Cyclooxygenase-2 expression in Barrett's esophagus
66. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
67. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus
68. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
69. Prostaglandin E production by Lewis lung carcinoma: Mechanism for tumor establishment, in vivo
70. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
71. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): A potential mechanism for their antineoplastic properties
72. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung
73. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
74. Expression of cyclooxygenase-2 in human lung carcinoma
75. A selective cyclooxygenase-2 inhibitor, ns-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2
76. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer
77. Nonsteroidal antiinflammatory drugs and breast cancer
78. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer
79. Prospective study of regular aspirin use and the risk of breast cancer
80. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats
81. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis
82. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
83. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model
84. COX-2 is expressed in human pulmonary, colonic, and mammary tumors
85. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer
86. Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase
87. Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in rats
88. Effect of aspirin on N-[4-(5-nitro-2-furyl)2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat
89. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats
90. Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam
91. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder
92. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
93. Expression of cyclooxygenase-2 in human ransitional cell carcinoma of the urinary bladder
94. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder
95. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder
96. The role of cyclooxygenase-2 in prostate cancer
97. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
98. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
99. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate
100. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer
101. Expression of cyclooxygenase-2 in prostate carcinoma
102. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells
103. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
104. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study
105. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis
106. Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes
107. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression
108. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin
109. Ultraviolet B (UVB)-induced cox-2 expression in murine skin: An immunohistochemical study
110. Immunohistochemical analysis of cyclooxygenase expression in human skin
111. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
112. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition
113. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
114. Combinatorial chemoprevention of intestinal neoplasia
115. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
116. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells
117. Detection of altered retinoic acid receptor expression in tissue sections using in situ hybridization
118. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines
119. Human lung cancer cell lines exhibit resistance to retinoic acid treatment
120. Targeting angiogenic processes by combination rofecoxib and ionizing radiation
121. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor
122. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos